Michael Alrutz
Algemeen Adviseur bij CHIMERIX, INC.
Vermogen: 118 115 $ op 30-04-2024
Profiel
Michael A.
Alrutz is currently the Secretary, Senior Vice President & General Counsel at Chimerix, Inc. He previously worked as the General Counsel at Trimeris, Inc. from 2002 to 2011.
He completed his undergraduate degree at the University of Pennsylvania, his graduate degree at Duke University School of Law, and his doctorate at the Sackler School of Graduate Biomedical Sciences.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
CHIMERIX, INC.
0.15% | 31-03-2024 | 132 564 ( 0.15% ) | 118 115 $ | 30-04-2024 |
Actieve functies van Michael Alrutz
| Bedrijven | Functie | Begin |
|---|---|---|
| CHIMERIX, INC. | Algemeen Adviseur | 01-06-2012 |
Eerdere bekende functies van Michael Alrutz
| Bedrijven | Functie | Einde |
|---|---|---|
Trimeris, Inc.
 Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Algemeen Adviseur | 04-11-2011 |
Opleiding van Michael Alrutz
| University of Pennsylvania | Undergraduate Degree |
| Duke University School of Law | Graduate Degree |
| Sackler School of Graduate Biomedical Sciences | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CHIMERIX, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Health Technology |
